{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:43:44Z","timestamp":1782366224715,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["T-B-077"],"award-info":[{"award-number":["T-B-077"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2023-I2M-C"],"award-info":[{"award-number":["2023-I2M-C"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1-014"],"award-info":[{"award-number":["2021-I2M-1-014"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2022-I2M-2-002"],"award-info":[{"award-number":["2022-I2M-2-002"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005149","name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["CICAMS-MOMP2022003"],"award-info":[{"award-number":["CICAMS-MOMP2022003"]}],"id":[{"id":"10.13039\/501100005149","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L258033"],"award-info":[{"award-number":["L258033"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.canlet.2026.218327","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:15:37Z","timestamp":1771460137000},"page":"218327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial"],"prefix":"10.1016","volume":"645","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7842-6883","authenticated-orcid":false,"given":"Xuemin","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7301-4118","authenticated-orcid":false,"given":"Jianming","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-337X","authenticated-orcid":false,"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.canlet.2026.218327_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.canlet.2026.218327_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100114","article-title":"Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort","volume":"6","author":"Grinda","year":"2021","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.canlet.2026.218327_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.3428","article-title":"Effectiveness of adding everolimus to the first-line treatment of advanced breast cancer in premenopausal women who experienced disease progression while receiving selective estrogen receptor modulators: a phase 2 randomized clinical trial","volume":"7","author":"Fan","year":"2021","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218327_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2014.60.1971","article-title":"Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-Negative advanced breast cancer: results from BOLERO-2","volume":"34","author":"Hortobagyi","year":"2016","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"issue":"16","key":"10.1016\/j.canlet.2026.218327_bib5","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","article-title":"Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer","volume":"27","author":"Baselga","year":"2009","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.canlet.2026.218327_bib6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/annonc\/mdu497","article-title":"Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer","volume":"26","author":"Treilleux","year":"2015","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"issue":"1","key":"10.1016\/j.canlet.2026.218327_bib7","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1038\/s41467-022-33365-y","article-title":"The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.canlet.2026.218327_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005052","article-title":"Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma","volume":"10","author":"Beasley","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2026.218327_bib9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1186\/s12967-023-04395-x","article-title":"Identifying prognostic markers in spatially heterogeneous breast cancer microenvironment","volume":"21","author":"Liu","year":"2023","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.canlet.2026.218327_bib10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s43018-021-00190-z","article-title":"Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response","volume":"2","author":"McNamara","year":"2021","journal-title":"Nat. Cancer"},{"issue":"12","key":"10.1016\/j.canlet.2026.218327_bib11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"issue":"W1","key":"10.1016\/j.canlet.2026.218327_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2026.218327_bib13","article-title":"Fast gene set enrichment analysis","author":"Korotkevich","year":"2021","journal-title":"bioRxiv"},{"issue":"6","key":"10.1016\/j.canlet.2026.218327_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"issue":"6","key":"10.1016\/j.canlet.2026.218327_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218327_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."},{"issue":"9","key":"10.1016\/j.canlet.2026.218327_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006436","article-title":"Condition-adaptive fused graphical lasso (CFGL): an adaptive procedure for inferring condition-specific gene co-expression network","volume":"14","author":"Lyu","year":"2018","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.canlet.2026.218327_bib18","series-title":"Igraph for R: R Interface of the Igraph Library for Graph Theory and Network Analysis","author":"Cs\u00e1rdi","year":"2023"},{"issue":"2","key":"10.1016\/j.canlet.2026.218327_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.canlet.2026.218327_bib20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00018-022-04477-x","article-title":"C-type lectin domain-containing protein CLEC3A regulates proliferation, regeneration and maintenance of nucleus pulposus cells","volume":"79","author":"Chen","year":"2022","journal-title":"Cell. Mol. Life Sci. : CM"},{"issue":"5","key":"10.1016\/j.canlet.2026.218327_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.06.085","article-title":"NOX1-Dependent mTORC1 activation via S100A9 oxidation in cancer stem-like cells leads to Colon cancer progression","volume":"28","author":"Ohata","year":"2019","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.canlet.2026.218327_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bjc.6606014","article-title":"The role of FKBP5 in cancer aetiology and chemoresistance","volume":"104","author":"Li","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2026.218327_bib23","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.devcel.2010.03.008","article-title":"FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and rictor","volume":"18","author":"Chen","year":"2010","journal-title":"Dev. Cell"},{"issue":"1","key":"10.1016\/j.canlet.2026.218327_bib24","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1038\/s41598-022-05949-7","article-title":"NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer","volume":"12","author":"Bhat","year":"2022","journal-title":"Sci. Rep."},{"issue":"28","key":"10.1016\/j.canlet.2026.218327_bib25","doi-asserted-by":"crossref","first-page":"25815","DOI":"10.18632\/oncotarget.4441","article-title":"SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients","volume":"6","author":"Chan","year":"2015","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.canlet.2026.218327_bib26","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1101\/gad.267708.115","article-title":"CALML5 is a ZNF750- and TINCR-induced protein that binds stratifin to regulate epidermal differentiation","volume":"29","author":"Sun","year":"2015","journal-title":"Gene Dev."},{"key":"10.1016\/j.canlet.2026.218327_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cytogfr.2021.01.005","article-title":"Secretory Leukocyte protease inhibitor (SLPI) in mucosal tissues: protects against inflammation, but promotes cancer","volume":"59","author":"Nugteren","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.canlet.2026.218327_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/path.6207","article-title":"The collagen landscape in cancer: profiling collagens in tumors and in circulation reveals novel markers of cancer-associated fibroblast subtypes","volume":"262","author":"Thorlacius-Ussing","year":"2024","journal-title":"J. Pathol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218327_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41374-021-00699-y","article-title":"Matrix metalloproteinase 11 (MMP11) in macrophages promotes the migration of HER2-positive breast cancer cells and monocyte recruitment through CCL2-CCR2 signaling","volume":"102","author":"Kang","year":"2022","journal-title":"Lab. Invest."},{"issue":"6","key":"10.1016\/j.canlet.2026.218327_bib30","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/his.13956","article-title":"MMP11 expression in intratumoral inflammatory cells in breast cancer","volume":"75","author":"Eiro","year":"2019","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.canlet.2026.218327_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3892\/or.2020.7640","article-title":"Small breast epithelial mucin promotes the invasion and metastasis of breast cancer cells via promoting epithelial-to-mesenchymal transition","volume":"44","author":"Li","year":"2020","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.canlet.2026.218327_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/bcr3618","article-title":"Clinical development of mTOR inhibitors in breast cancer","volume":"16","author":"Vicier","year":"2014","journal-title":"Breast Cancer Res."},{"issue":"13","key":"10.1016\/j.canlet.2026.218327_bib33","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.canlet.2026.218327_bib34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2026.218327_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.canlet.2026.218327_bib36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41408-023-00962-z","article-title":"Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in acute myeloid leukemia","volume":"13","author":"Fan","year":"2023","journal-title":"Blood Cancer J."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600090X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600090X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:55:11Z","timestamp":1778684111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352600090X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"alternative-id":["S030438352600090X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218327","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218327"}}